Can I Take CoQ10 with Farxiga (Dapagliflozin)?

What Is Farxiga and How Does It Work?

Dapagliflozin (Farxiga) blocks the sodium-glucose cotransporter 2 (SGLT2) in the proximal tubule of the kidney, preventing glucose reabsorption and causing it to be excreted in urine. The FDA approved dapagliflozin for type 2 diabetes in 2014, for heart failure with reduced ejection fraction in 2020, and for chronic kidney disease in 2021 [1].

Farxiga's Cardiovascular and Renal Profile

The DECLARE-TIMI 58 trial (N=17,160) showed dapagliflozin reduced the composite of cardiovascular death or worsening heart failure by 17% versus placebo over a median 4.2 years (hazard ratio 0.83, 95% CI 0.73 to 0.95, P<0.001) [2]. The DAPA-CKD trial (N=4,304) demonstrated a 39% relative risk reduction in the composite kidney endpoint compared with placebo (P<0.001) [3]. These data explain why Farxiga is now prescribed across a broad patient population that often carries multiple comorbidities and takes several other drugs and supplements.

How Farxiga Is Metabolized

Dapagliflozin is primarily metabolized by UGT1A9, a uridine diphosphate glucuronosyltransferase enzyme, to its inactive glucuronide metabolite. The drug is not a clinically significant substrate or inhibitor of CYP3A4, CYP2C9, P-glycoprotein, or other major drug-metabolizing enzymes according to the FDA prescribing information [1]. That metabolic profile matters when evaluating potential supplement interactions, because many supplement-drug interactions operate through CYP450 pathways.

What Is CoQ10 and Why Do Farxiga Patients Ask About It?

CoQ10 is a fat-soluble compound found in virtually every cell. It sits in the inner mitochondrial membrane and transfers electrons in the electron transport chain, making it essential for ATP production [4]. Plasma CoQ10 levels in healthy adults average roughly 0.75 to 1.0 micromol/L, and deficiency has been associated with heart failure, statin use, and metabolic disease [5].

The Statin-CoQ10 Connection

Many patients on Farxiga are also prescribed a statin, because cardiovascular risk reduction is a standard goal in type 2 diabetes and CKD management. Statins inhibit HMG-CoA reductase, the same pathway used to synthesize CoQ10, and trials have shown statin therapy reduces plasma CoQ10 by approximately 25 to 50% depending on dose and duration [6]. A randomized crossover study (N=32) published in the American Journal of Cardiology found that atorvastatin 80 mg reduced plasma CoQ10 by 49% over 30 days compared with baseline [7]. Patients who notice new fatigue or muscle aches after starting a statin frequently ask their provider about CoQ10, which then raises the question of whether it is safe alongside Farxiga.

CoQ10 and Cardiometabolic Disease

CoQ10 supplementation has been studied specifically in populations similar to those taking Farxiga. The Q-SYMBIO trial (N=420) randomized patients with moderate-to-severe heart failure to CoQ10 300 mg/day or placebo for two years. The CoQ10 group had a 43% reduction in major adverse cardiovascular events (hazard ratio 0.50, 95% CI 0.32 to 0.80, P<0.003) and lower all-cause mortality [8]. That trial enrolled patients with New York Heart Association class III-IV symptoms, so its findings may not apply uniformly to all Farxiga patients, but the data establish a biological rationale for CoQ10 use in the overlap population.

Is There a Drug Interaction Between CoQ10 and Farxiga?

No pharmacokinetic interaction between CoQ10 and dapagliflozin has been identified in the peer-reviewed literature or in the FDA-approved labeling for Farxiga [1]. The absence of evidence is scientifically coherent: CoQ10 does not meaningfully inhibit or induce UGT1A9, and dapagliflozin does not alter CoQ10 absorption or metabolism. The concern worth examining is pharmacodynamic, not pharmacokinetic.

Pharmacokinetic Interaction: None Identified

CoQ10 is absorbed in the small intestine, incorporated into chylomicrons, and distributed via the lymphatic system before entering systemic circulation [9]. Its bioavailability is highly variable (approximately 2 to 4% for crystalline forms, and higher for oil-based or nanoemulsion preparations) and is not affected by the renal SGLT2 transporter that dapagliflozin blocks [9]. Because dapagliflozin's elimination relies on UGT1A9 glucuronidation rather than CYP enzymes, and CoQ10 does not meaningfully inhibit UGT1A9 at physiological concentrations, no clinically relevant change in dapagliflozin plasma levels is expected [1].

Pharmacodynamic Consideration: Blood Pressure Overlap

Both dapagliflozin and CoQ10 have documented antihypertensive effects, and the combination could amplify blood pressure lowering in susceptible patients. A 2007 meta-analysis of 12 clinical trials (N=362) found CoQ10 supplementation reduced systolic blood pressure by a mean of 16.6 mmHg and diastolic blood pressure by 8.2 mmHg, though study quality was variable [10]. Dapagliflozin itself reduces systolic blood pressure by approximately 3 to 4 mmHg through osmotic diuresis and natriuresis, as quantified in the DECLARE-TIMI 58 trial [2]. Patients who are already on antihypertensive agents, have orthostatic hypotension, or are elderly face the most meaningful risk of additive blood pressure lowering. Monitoring is straightforward: check sitting and standing blood pressure at the first follow-up after adding CoQ10.

Glycemic Effects of CoQ10

Some evidence suggests CoQ10 may modestly improve insulin sensitivity. A meta-analysis of randomized controlled trials published in Diabetes, Obesity and Metabolism (12 trials, N=684) found CoQ10 supplementation produced a mean reduction in fasting blood glucose of 0.18 mmol/L (95% CI 0.01 to 0.36, P=0.04) compared with placebo [11]. That effect is small relative to dapagliflozin's glucose-lowering potency, but it is worth monitoring in patients whose HbA1c is already well-controlled, as the combination could theoretically increase the frequency of mild hypoglycemia. SGLT2 inhibitors alone carry a low intrinsic hypoglycemia risk because their mechanism is insulin-independent, but the additive glucose-lowering warrants attention [1].

Who Is Most Likely to Be Taking Both?

The overlap population is not theoretical. Type 2 diabetes, heart failure, and CKD frequently co-occur, and patients in those groups are commonly prescribed statins, which deplete CoQ10 and create the most frequent clinical reason to add the supplement. Consider the following typical patient profile:

• Farxiga 10 mg/day for type failure with reduced ejection fraction
• Atorvastatin 40 mg/day for cardiovascular risk reduction
• Low plasma CoQ10 due to statin-mediated HMG-CoA reductase inhibition [6]
• Provider or self-initiated CoQ10 supplementation at 100 to 200 mg/day

For this patient, the relevant interactions are statin-CoQ10 (the statin depletes CoQ10, so replacement is the goal) and the pharmacodynamic additive antihypertensive effect shared by dapagliflozin and CoQ10. Neither is a hard contraindication. Both are manageable with monitoring.

The American Heart Association's 2022 scientific statement on dietary supplements and cardiovascular disease notes that CoQ10 supplementation in heart failure patients "warrants further study" but does not list it as contraindicated with any specific pharmacological agent class [12].

The HealthRX clinical team uses the following decision framework when a patient on Farxiga asks about adding CoQ10:

Step 1. Confirm the indication for CoQ10 (statin-related CoQ10 depletion, heart failure support, or general antioxidant use).

Step 2. Review baseline blood pressure. If systolic blood pressure is consistently below 110 mmHg or the patient has documented orthostatic hypotension, CoQ10 should be started at a lower dose (100 mg/day) with a blood pressure recheck within 2 weeks.

Step 3. Review baseline HbA1c and fasting glucose. If HbA1c is below 6.5% on current therapy, discuss the modest additive glucose-lowering potential with the patient.

Step 4. Choose a bioavailable CoQ10 formulation. Oil-suspended or ubiquinol forms absorb better than crystalline ubiquinone, and adequate absorption is necessary to achieve the plasma levels studied in cardiovascular trials [9].

Step 5. Recheck blood pressure and fasting glucose at the 4-week visit after starting CoQ10. Adjust antihypertensives if needed.

Dose and Formulation Considerations for CoQ10

How Much CoQ10 Is Studied?

Published cardiovascular and metabolic trials have used a wide range of CoQ10 doses. The Q-SYMBIO trial used 300 mg/day in divided doses [8]. A meta-analysis of CoQ10 in hypertension used studies ranging from 60 to 360 mg/day [10]. For statin-related CoQ10 depletion, most clinical protocols use 100 to 200 mg/day, though higher doses have been evaluated [6]. The FDA classifies CoQ10 as generally recognized as safe (GRAS) at these doses, and the Farxiga prescribing information does not list any dietary supplement as a contraindicated co-administration [1].

Ubiquinone vs. Ubiquinol

CoQ10 exists in two forms in commercial supplements: ubiquinone (the oxidized form) and ubiquinol (the reduced, active form). A pharmacokinetic crossover study (N=33) published in Regulatory Toxicology and Pharmacology found ubiquinol produced peak plasma CoQ10 concentrations roughly 2-fold higher than equivalent ubiquinone doses [13]. For patients with gastrointestinal absorption issues common in CKD or heart failure, ubiquinol formulations may be more clinically relevant, though both forms are considered safe and neither interacts pharmacokinetically with dapagliflozin.

Timing of Doses

CoQ10 is fat-soluble, so it should be taken with a meal containing dietary fat to maximize absorption [9]. Dapagliflozin can be taken with or without food and has no food-timing restrictions per its prescribing label [1]. Taking both at the same meal is acceptable and does not create a pharmacokinetic conflict. No dose-separation window is clinically indicated.

What the Farxiga Prescribing Information Says About Supplements

The FDA-approved prescribing information for dapagliflozin lists no dietary supplement interactions [1]. Formal drug interaction studies performed before approval tested co-administration with metformin, pioglitazone, sitagliptin, glimepiride, voglibose, hydrochlorothiazide, bumetanide, valsartan, and simvastatin, none of which revealed clinically significant pharmacokinetic interactions [1]. CoQ10 was not studied, which is common for supplements in pharmaceutical approval programs. The absence of a listed interaction does not guarantee safety, but it does mean there is no regulatory signal of concern.

Monitoring Recommendations When Taking CoQ10 with Farxiga

Routine monitoring already recommended for Farxiga patients covers most of what is needed when adding CoQ10. The Farxiga prescribing information recommends monitoring renal function, blood pressure, and signs of volume depletion [1]. The ADA's 2024 Standards of Care in Diabetes recommend HbA1c testing every 3 months until stable, then every 6 months [14]. Blood glucose self-monitoring frequency should match the patient's treatment complexity.

Specific additions when co-prescribing CoQ10:

• Blood pressure. Recheck within 2 to 4 weeks if the patient is on multiple antihypertensive agents or has a history of orthostatic hypotension.
• Fasting glucose or HbA1c. No additional frequency beyond guideline-recommended intervals unless the patient reports hypoglycemic symptoms.
• Statin-related muscle symptoms. If CoQ10 is being added to address statin myopathy, document baseline creatine kinase (CK) levels and reassess at 4 to 8 weeks [6].
• Supplement quality. Advise patients to choose products verified by NSF International, USP, or ConsumerLab, as CoQ10 supplement content can deviate substantially from label claims in unverified products [15].

Special Populations

Patients with CKD

Dapagliflozin is approved for CKD at an estimated glomerular filtration rate (eGFR) as low as 25 mL/min/1.73 m² based on DAPA-CKD data [3]. CoQ10 is renally cleared to a minimal degree, and no dose adjustment is recommended in CKD, though formal pharmacokinetic data in advanced CKD are limited [4]. Given that CKD patients may have baseline hypotension and volume depletion from concurrent diuretic therapy, blood pressure monitoring is especially relevant in this group.

Patients with Heart Failure

The Q-SYMBIO trial specifically enrolled heart failure patients and found benefit with CoQ10 300 mg/day over two years [8]. Dapagliflozin is also approved and effective in heart failure with reduced ejection fraction based on the DAPA-HF trial (N=4,744), which showed a 26% relative risk reduction in the composite of worsening heart failure or cardiovascular death versus placebo (P<0.001) [16]. Both therapies have overlapping beneficial populations. Blood pressure monitoring remains the primary co-prescription precaution.

Older Adults

Adults over 65 are more likely to experience orthostatic hypotension with both agents. A prospective observational study published in the Journal of the American Geriatrics Society found that SGLT2 inhibitor use was associated with a 2.4-fold higher risk of orthostatic hypotension-related falls in adults over 75 in the 90 days after initiation compared with younger patients [17]. Adding CoQ10's modest antihypertensive effect in this context warrants extra caution and a lower starting dose.

What to Tell Your Doctor

Bring a complete supplement list to every prescriber visit. The 2020 AHA scientific advisory on supplement use in cardiovascular patients found that 69% of patients do not disclose dietary supplement use to their cardiologist unless directly asked [12]. For Farxiga patients specifically:

• Tell your provider the CoQ10 dose and formulation you plan to use or are already using.
• Report any new dizziness, lightheadedness, or unusual fatigue after starting CoQ10, as these may reflect additive blood pressure lowering.
• Do not stop Farxiga to accommodate a supplement. The cardiovascular and renal mortality benefits of dapagliflozin documented in DECLARE-TIMI 58, DAPA-HF, and DAPA-CKD represent outcomes that far outweigh any theoretical concern about co-administering CoQ10.

The FDA's MedWatch program is available for patients and providers who wish to report suspected adverse events from supplement-drug combinations [18].